Afexa, Paladin, Valeant Pharmaceuticals deal

Valeant began its tender offer to acquire Afexa for C$0.71 per share in cash, or about C$76 million ($75.9 million). The offer expires at 5 p.m. MST on Oct. 17. Separately last week, Paladin extended ...